Science Explorer Interactive view Map
Topic · Oncology

PARP inhibition in cancer therapy

PARP inhibition in cancer therapy is a research topic within Oncology. Science Explorer counts 19k research works in it since 1951. 23.0% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the use of Poly(ADP-ribose) Polymerase (PARP) inhibitors, such as Olaparib and Niraparib, as a targeted therapy for cancer, particularly in the context of BRCA mutations and DNA repair deficiency. The concept of synthetic lethality, homologous recombination, and the therapeutic potential of PARP inhibitors in various cancers, including platinum-sensitive ovarian cancer, are extensively explored.

  • PARP Inhibitors
  • BRCA Mutation
  • DNA Repair
  • Olaparib
  • Synthetic Lethality
  • Homologous Recombination
  • Cancer Therapy
  • Platinum-Sensitive Ovarian Cancer
  • BRCA1/2 Deficiency
  • Cell Death
Research works
19k
fractional, since 1951
In the world top 10%
4.3k
per year above
Top-10% rate
23.0%
share of its works in the world top 10%
Growth, 2013–17 → 2018–22
+63%
the tick is no change

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead PARP inhibition in cancer therapy research?

By volume, the United States and China publish the most (1.3k and 965 works in 2022–2025).

By volume, 2022–2025

  1. 1 United States 1.3k works
  2. 2 China 965 works
  3. 3 Italy 232 works
  4. 4 United Kingdom 223 works
  5. 5 Germany 200 works
  6. 6 Japan 193 works
  7. 7 India 190 works
  8. 8 France 147 works
  9. 9 South Korea 140 works
  10. 10 Canada 127 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 35.6%China: 25.7%Italy: 6.2%United Kingdom: 5.9%6 others listed: 26.5%36%largest
United States1,337 · 35.6%China965 · 25.7%Italy232 · 6.2%United Kingdom223 · 5.9%6 others listed996 · 26.5%

Shares of the rows listed above, not of the whole node.

Which institutions lead PARP inhibition in cancer therapy research?

By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most PARP inhibition in cancer therapy research, followed by Chinese Academy of Medical Sciences & Peking Union Medical College and Dana-Farber Cancer Institute.

By volume, 2022–2025

  1. 1 The University of Texas MD Anderson Cancer CenterUnited States 48 works
  2. 2 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 28 works
  3. 3 Dana-Farber Cancer InstituteUnited States 27 works
  4. 4 Memorial Sloan Kettering Cancer CenterUnited States 25 works
  5. 5 Sun Yat-sen UniversityChina 20 works
  6. 6 University of PennsylvaniaUnited States 20 works
  7. 7 Harvard UniversityUnited States 20 works
  8. 8 Washington University in St. LouisUnited States 19 works
  9. 9 The University of Texas Southwestern Medical CenterUnited States 18 works
  10. 10 University of California, San FranciscoUnited States 18 works

Who are the leading researchers in PARP inhibition in cancer therapy?

The most-cited researchers publishing on PARP inhibition in cancer therapy include Gordon B. Mills, Larry Rubinstein and David R. Spigel.

  1. 1 Gordon B. Mills United States 3.7k citations
  2. 2 Larry Rubinstein United States 3.6k citations
  3. 3 David R. Spigel United States 3.2k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

Where is PARP inhibition in cancer therapy research done?

The largest centres of PARP inhibition in cancer therapy research in 2022–2025 are Beijing (China), Shanghai (China), London (United Kingdom) and Seoul (South Korea). Among places with at least 20 works in it, it is an unusually large share of all research in Bethesda, Heidelberg and Dallas.

Largest cities, 2022–2025

  1. 1 Beijing China 117 works
  2. 2 Shanghai China 92 works
  3. 3 London United Kingdom 81 works
  4. 4 Seoul South Korea 79 works
  5. 5 New York United States 77 works
  6. 6 Guangzhou China 73 works
  7. 7 Boston United States 73 works
  8. 8 Houston United States 64 works
  9. 9 Philadelphia United States 55 works
  10. 10 Nanjing China 52 works

Where it is the local speciality

  1. BethesdaUS · 36.8 works6.5×
  2. HeidelbergDE · 30.1 works6.4×
  3. DallasUS · 21.7 works6.0×
← less than its size predicts1×more →

Location quotient: how much more of its research is in PARP inhibition in cancer therapy than the world average.

See PARP inhibition in cancer therapy on the map

Where is the best place to study PARP inhibition in cancer therapy?

Among universities, judged by research, Oregon Health & Science University, China Pharmaceutical University and Chinese Academy of Medical Sciences & Peking Union Medical College score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 25.78%fractional works in this node (log) →share in the world top 10% →Oregon Health & Science University: 12, 21.8%China Pharmaceutical University: 12, 31.5%Chinese Academy of Medical Sciences & Peking Union Medical College: 28, 19.8%Institute of Cancer Research: 11, 20.8%University of Pennsylvania: 20, 19.0%University of Oxford: 9, 47.0%Cornell University: 14, 33.5%Université de Montréal: 9, 22.9%Harvard University: 20, 28.9%University of California, San Francisco: 18, 12.6%China Pharmaceutical…Oregon Health & Scie…Institute of Cancer …Chinese Academy of M…
above the meannear itbelow it

One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.

#UniversityScoreTop 10%SpecialisationWorksGrowth
1 Oregon Health & Science UniversityUnited States 55.821.8%9.1×12 +302.6%
2 China Pharmaceutical UniversityChina 53.831.5%12.3×12 +34.0%
3 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 51.019.8%6.4×28 +125.3%
4 Institute of Cancer ResearchUnited Kingdom 47.820.8%74.4×11 -13.7%
5 University of PennsylvaniaUnited States 47.319.0%4.8×20 +314.8%
6 University of OxfordUnited Kingdom 45.147.0%1.6×9 +80.7%
7 Cornell UniversityUnited States 42.633.5%3.1×14 +75.1%
8 Université de MontréalCanada 42.522.9%4.7×9 +239.9%
9 Harvard UniversityUnited States 41.328.9%3.4×20 +14.6%
10 University of California, San FranciscoUnited States 37.812.6%6.1×18 +70.7%

Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.

Is PARP inhibition in cancer therapy research growing?

Output in 2018–2022 was 63% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are PARP inhibition in cancer therapy.

19801990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.